Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

tranexamic acid

A synthetic derivative of the amino acid lysine with antifibrinolytic activity. With strong affinity for the five lysine-binding sites of plasminogen, tranexamic acid competitively inhibits the activation of plasminogen to plasmin, resulting in inhibition of fibrinolysis; at higher concentrations, this agent noncompetitively inhibits plasmin. This agent has a longer half-life, is approximately ten times more potent, and is less toxic than aminocaproic acid, which possesses similar mechanisms of action.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:tranhexamic acid
US brand name:Cyklokapron
Lysteda
Foreign brand name:Amixam
Cyclokapron
Hemostan
Prexam
Tranofast
Chemical structure:cyclohexanecarboxylic acid, 4-(aminomethyl)-, trans-
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search